CHina Adrenal Venous saMPling InvestigatiON
China Adrenal Venous Sampling Investigation: A National Multicenter Study
Chinese Academy of Medical Sciences, Fuwai Hospital
5,000 participants
May 1, 2025
OBSERVATIONAL
Conditions
Summary
Primary aldosteronism (PA) is a major cause of secondary hypertension, yet its optimal diagnosis and management remain challenging. This study comprehensively evaluates adrenal venous sampling (AVS), addressing key clinical, technical, and methodological issues, and aims to clarify the relationship between AVS-guided management and long-term clinical and biochemical outcomes to optimize patient care and prognosis.
Eligibility
Inclusion Criteria2
- Patients with confirmed primary aldosteronism;
- Patients undergoing adrenal venous sampling for subtype classification of primary aldosteronism.
Exclusion Criteria6
- Severe comorbidity, including stroke, myocardial infarction, heart failure, severe valvular heart disease, liver cirrhosis, and metastatic tumor within the previous 3 months；
- An estimated glomerular filtration rate <45 ml/min/1.73 m2, or serum creatinine >176 μmol/L；
- Patients who refuse adrenalectomy;
- Suspected of having an adrenocortical carcinoma;
- Allergy to contrast agent;
- Pregnant, nursing, or planning to become pregnant
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Patients with Primary Aldosteronism (PA) undergoing Adrenal Venous Sampling via antecubital approach or femoral approach to discriminate PA forms with unilateral from bilateral excess aldosterone production.
Locations(76)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07252284